Pulmonary Embolism Clinical Trial
Official title:
Assessing the Risk of Pulmonary Embolism in Patients After Hospitalization for First Episode of Syncope
Verified date | January 2017 |
Source | Rambam Health Care Campus |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Acute pulmonary embolism (APE) is a common disease, which involves significant morbidity and
mortality. The clinical presentation of APE has many faces but it is acceptable to suspect
this disease when the patient presenting with at least one of the following: shortness of
breath, pleuritic chest pain, cough, sub-febrile fever or hemoptysis.
The relationship between syncope and APE is not entirely clear. Prandoni et al conducted a
systematic process for the exclusion / confirmation of APE all patients hospitalized for a
first investigation of syncope. In this study APE was diagnosed in about 17% of the
patients. In 12.7% of patients with an alternative explanation for syncope APE was
diagnosed. Interestingly, 25% of the patients had no other manifestation of pulmonary
embolism apart from the syncope itself.
According to the updated clinical guidelines, APE should not be routinely tested as an
etiology for syncope and not systematically excluded. According to the new data presented by
Prandoni et al, this means that a significant percentage of patients hospitalized for an
investigation of syncope are discharged when they are suffering from APE (in most cases
probably an event of unprovoked pulmonary embolism) without treatment with anticoagulants,
making them particularly prone to PE recurrence.
Aim. To examine the incidence of pulmonary embolism (Pulmonary Embolism, PE), and VTE
(venous thromboembolism, VTE) in patients hospitalized for a first investigation of syncope.
Status | Not yet recruiting |
Enrollment | 7000 |
Est. completion date | February 1, 2018 |
Est. primary completion date | February 1, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients over 18 years old during study period. * On admission diagnosis of syncope and collapse (ICD9 code 427.31). - Patients are insured by Clalit Health Services. Exclusion Criteria: * Hospitalization during the study period for additional event of syncope. - Patients receiving anticoagulation on recruitment. - Patients investigated for APE during hospitalization (by testing for D-dimer, computerized tomography angiography or perfusion-ventilation lung scan). - Patients who began treatment anticoagulation, not because of VTE, during study period. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Rambam Health Care Campus |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | venous thromboembolism | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05050617 -
Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
|
||
Terminated |
NCT04558125 -
Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism
|
Phase 4 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Completed |
NCT03915925 -
Short-term Clinical Deterioration After Acute Pulmonary Embolism
|
||
Completed |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
||
Recruiting |
NCT05171075 -
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
|
Phase 3 | |
Completed |
NCT04454554 -
Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
|
||
Completed |
NCT03173066 -
Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography
|
Phase 1 | |
Terminated |
NCT03002467 -
Impact Analysis of Prognostic Stratification for Pulmonary Embolism
|
N/A | |
Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
Completed |
NCT02611115 -
Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography.
|
N/A | |
Completed |
NCT01975090 -
The SENTRY Clinical Study
|
N/A | |
Not yet recruiting |
NCT01357941 -
Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE)
|
N/A | |
Completed |
NCT01326507 -
Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism
|
N/A | |
Completed |
NCT02476526 -
Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00780767 -
Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism
|
Phase 2 | |
Completed |
NCT00720915 -
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
|
N/A | |
Completed |
NCT00771303 -
Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
|
||
Completed |
NCT00773448 -
Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism
|
N/A | |
Completed |
NCT00816920 -
Natural History of Isolated Deep Vein Thrombosis of the Calf
|